

How are clinical trials for breast cancer treatments currently being designed? A clinical trial database analysis

Charlotte Verbeke^{1,*}, Justine De Tavernier¹, Annette Eeraerts¹, Lara Torfs¹, Patrick Neven², Isabelle Huys¹


¹Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium

²Department of Obstetrics and Gynaecology, Division of Gynaecological Oncology, University Hospitals Leuven, Belgium

*Contact: charlotte.verbeke@kuleuven.be

BACKGROUND & OBJECTIVE

- Breast cancer is highly prevalent among women, with an impact on patients' quality of life
- New treatments developed and tested in clinical trials
- Provide a **comprehensive overview of breast cancer clinical trials**
 - How are the clinical trials **designed**?
 - What are the **endpoints** in the clinical trials?
 - Whether **patients are involved** in clinical trials
 - If and how **patients' needs and QoL** are assessed



METHODS - *Database analysis*

- **Database:** ClinicalTrials.gov
- Search conducted **November 2024**

Applied filters in ClinicalTrials.gov	
(i)	female
(ii)	adult participants (18-64 years old)
(iii)	completed trials
(iv)	trials with results
(v)	phase III and phase IV
(vi)	interventional studies

*Important note: All filters represent minimum inclusion requirements; broader study characteristics (e.g., wider age ranges or both sexes) were allowed.

- Systematically **screening** of the trials after applying the filters
- **Data extraction** in a predefined excel table
- **Patient involvement** was assessed by evaluating secondary endpoints in the clinical trials

RESULTS - *preliminary findings*

- 280 trials were identified and analysed
- Included trials started between 1997-2021

Clinical trials (N=280)	
<i>Clinical phase</i>	
Phase III	244 (87%)
Phase IV	36 (13%)
<i>Primary purpose of clinical trial</i>	
Treatment	216 (77%)
Supportive care	32 (11%)
Prevention	14 (5%)
Diagnostic	11 (4%)
Other/Not specified	7 (3%)
<i>Most mentioned treatment categories in the clinical trials (also in combinations)</i>	
Chemotherapy	114
Targeted therapy	117
Hormonal therapy	64

➢ Number of participants in the trial

- Median: 433,5
- 9 (min) – 9779 (max)

➢ Follow up time

- Median: 39 months
- 6 hours (min) – 190 months (max)

➢ Breast cancer subtype included in trial – not specified in 151 trials

(co-)primary endpoints most identified

1 Progression free survival (64 trials)	3 Overall survival (23 trials)
2 Disease free survival (41 trials)	4 Pathologic complete response (16 trials)

Patient involvement

- Assessment of patients' needs and QoL via questionnaires (103 trials)
- Non-breast cancer specific questionnaires
- Cancer specific: EORTC QLQ-C30
- Non-disease specific: EQ-5D
- Non-disease specific: VAS
- Breast cancer specific questionnaires
- FACT-B
- EORTC-QLQ-BR23

CONCLUSIONS - *preliminary findings*

- Unclear elements in trial design (i.e., subtypes of breast cancer patients included)
- Strongly focussed on survival-based endpoints
- Limited information whether patients are involved and whether needs are evaluated

LIST OF ABBREVIATIONS

EORTC QLQ: European Organization for Research and Treatment for Cancer Quality of Life Questionnaire; EQ-5D: EuroQol 5D; FACT-B: Functional Assessment of Cancer Therapy – Breast; QoL: Quality of Life; VAS: Visual Analogue Scale

ACKNOWLEDGMENTS

This work is supported by KU Leuven and partly supported by the internal KU Leuven funding C3/22/052